Abstract:Background: Glofitamab is a T-cell-engaging bispecific monoclonal antibody with a novel 2:1 (CD20:CD3) configuration that confers bivalency for CD20 on B cells and monovalency for CD3 on T cells. Pivotal results from the global Phase I/II NP30179 study (NCT03075696) of glofitamab monotherapy indicate high response rates and manageable safety in patients with heavily pretreated, highly refractory diffuse large B-cell lymphoma (DLBCL); obinutuzumab pretreatment and Cycle (C) 1 step-up dosing effectively mitigated cytokine release syndrome (CRS; Dickinson et al. ASCO 2022). Here, we report results from a Phase I study (NCT04657302) of fixed-duration glofitamab monotherapy in Chinese patients with DLBCL after ≥2 prior lines of therapy. Methods: Eligible patients had DLBCL (DLBCL not otherwise specified [NOS]; high-grade B-cell lymphoma [HGBCL]; primary mediastinal B-cell lymphoma [PMBCL]; transformed follicular lymphoma [trFL]) and had received ≥2 prior regimens including ≥1 anti-CD20 antibody and ≥1 anthracycline. Patients received intravenous (IV) obinutuzumab pretreatment (1000mg) on C1 Day (D) 1, followed by step-up doses of IV glofitamab on C1D8 (2.5mg) and C1D15 (10mg), and the target dose (30mg) on D1 of C2-12 (21-day cycles). This study was designed to evaluate the pharmacokinetics (PK), safety, tolerability, and efficacy of fixed-duration glofitamab monotherapy. The primary efficacy endpoint was complete response (CR) rate as assessed by Independent Review Committee (IRC) using Lugano 2014 criteria (Cheson et al. J Clin Oncol 2014). Secondary efficacy endpoints included overall response rate (ORR), duration of complete response (DOCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Responses were assessed by PET-CT. CRS was assessed by ASTCT criteria (Lee et al. Biol Blood Marrow Transplant 2019). Other adverse events (AEs) were assessed by CTCAE v5.0. Results: As of May 30, 2022, 30 patients were enrolled, of whom 27 had been treated with ≥1 dose of glofitamab (median age: 58 years [range: 20-82]; Ann Arbor stage III-IV disease: 90%; Eastern Cooperative Oncology Group Performance Status 0/1: 50%/50%; bulky disease: 37%; DLBCL-NOS: 67%; HGBCL: 10%; PMBCL: 17%; trFL: 7%). Median number of prior therapies was 2 (range: 2-6), 67% of patients were primary refractory, 90% were refractory to their most recent regimen, and 20% had previously received chimeric antigen receptor T-cell (CAR-T) therapy (13% of these patients were refractory to CAR-T). The PK profile of glofitamab in Chinese patients appeared to be bi-phasic, and increased dosing (2.5mg‒30mg) showed dose-proportionality, which was also observed in the global NP30179 trial population. No post-dose anti-glofitamab anti-drug antibodies were identified. At data cut-off, the median follow-up was 10 months. Anti-tumor activity was observed in most patients (Figure). ORR and CR rates by IRC were 63% and 52%, respectively. Median time to CR was 43 days. Median DOR and DOCR were not reached. The majority of ORRs (13/17; 76%) and CRs (11/14; 79%) were ongoing at data cut-off. IRC-assessed median PFS was 8 months (95% CI: 3‒not evaluable [NE]). Median OS was 11 months (95% CI: 9‒NE). Serious AEs were reported in 43% of patients and there were no fatal AEs. AEs leading to treatment discontinuation were reported in two patients (7%). CRS events were the most common AEs (63%; grade [gr] 1: 57%; gr 2: 3%; gr 3: 3%), and all events were resolved at data cut-off. CRS events occurred predominantly during C1; no gr ≥2 CRS events occurred after C2. Neurologic AEs were reported in 27% of patients (gr 1: 17%; gr 2: 7%; gr 3: 3%). No glofitamab-related neurologic AEs potentially consistent with immune effector cell-associated neurotoxicity syndrome were reported. Conclusions: The PK profile of glofitamab in Chinese patients was similar to that reported in the global NP30179 pivotal cohort. Consistent with the NP30179 study, high response rates and durable responses were achieved in patients receiving glofitamab, and the safety profile of glofitamab in this Chinese population was manageable. These data suggest clinically meaningful outcomes with fixed-duration glofitamab monotherapy in heavily pretreated and highly refractory patients with R/R DLBCL from China. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Efficacy and Safety of Obinutuzumab for the First-Line Treatment of Follicular Lymphoma: a Subgroup Analysis of Chinese Patients Enrolled in the Phase III GALLIUM Study

Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.

A Prospective, Observational Study On The Safety And Effectiveness Of Rituximab Plus Chemotherapy As The First-Line Treatment Of Diffuse Large B-Cell Lymphoma

Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated Inhl: Final Results from the GALLIUM Study.

Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study

Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial

Obinutuzumab based immunochemotherapy prolongs progression free survival and time to next anti lymphoma treatment in patients with previously untreated follicular lymphoma …

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population with Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Efficacy and Safety of IBI110 in Combination with Sintilimab in First-Line Advanced HER2negative Gastric Cancer or Gastroesophageal Junction Cancer: Updated Results from a Phase Ib Study

Comparison of Zuberitamab Plus CHOP Versus Rituximab Plus CHOP for the Treatment of Drug-Naïve Patients Diagnosed with CD20-positive Diffuse Large B-cell Lymphoma: a Phase 3 Trial

Abstract CT114: Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Results of the Phase 3 CheckMate 078 Study

A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience.

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.

Glofitamab Monotherapy Demonstrates High Complete Response Rates and Manageable Safety in Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies

Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma

Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)

Sugemalimab Versus Placebo after Concurrent or Sequential Chemoradiotherapy in Patients with Locally Advanced, Unresectable, Stage III Non-Small-cell Lung Cancer in China (GEMSTONE-301): Interim Results of a Randomised, Double-Blind, Multicentre, Phase 3 Trial.

Management and Clinical Outcomes of Follicular Lymphoma Across Continuous Lines of Treatments: a Retrospective Analysis in China

First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis

Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study